1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/22033
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKiortisis, D. N.en
dc.contributor.authorMillionis, H.en
dc.contributor.authorBairaktari, E.en
dc.contributor.authorElisaf, M. S.en
dc.date.accessioned2015-11-24T19:20:22Z-
dc.date.available2015-11-24T19:20:22Z-
dc.identifier.issn0031-6970-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22033-
dc.rightsDefault Licence-
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectCholesterol/blooden
dc.subjectDrug Combinationsen
dc.subjectFemaleen
dc.subjectFenofibrate/administration & dosage/*therapeutic useen
dc.subjectFibrinogen/metabolismen
dc.subjectHeptanoic Acids/administration & dosage/*therapeutic useen
dc.subjectHumansen
dc.subjectHyperlipidemias/blood/*drug therapyen
dc.subjectHypolipidemic Agents/administration & dosage/*therapeutic useen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPyrroles/administration & dosage/*therapeutic useen
dc.subjectTriglycerides/blooden
dc.titleEfficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemiaen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11214768-
heal.identifier.secondaryhttp://www.springerlink.com/content/dq3ml5n61urx2fd7/fulltext.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2000-
heal.abstractOBJECTIVES: In patients with mixed lipid disorders, monotherapy may not effectively control all lipid abnormalities. We undertook this study to assess the efficacy of fenofibrate in combination with atorvastatin in patients with severe mixed dyslipidemia. METHODS: This was an 18-week, open-label study conducted in our lipid clinic. After a 6-week dietary baseline phase, patients received 200 mg/day micronised fenofibrate for 6 weeks. At the end of this period the subjects discontinued this treatment and received 40 mg/day atorvastatin for 6 weeks. Finally 200 mg/day of micronised fenofibrate was added to the statin therapy. RESULTS: Administration of micronised fenofibrate reduced serum triglycerides (P < 0.01) and total cholesterol and low-density lipoprotein (LDL) cholesterol (P < 0.05 for both parameters), while it evoked a significant increase in serum high-density lipoprotein (HDL) cholesterol levels (P < 0.05). Atorvastatin monotherapy induced a more pronounced decrease of total and LDL cholesterol. However, plasma triglycerides, although significantly lower than baseline values (P < 0.05), were higher than the values observed during treatment with fenofibrate. Moreover, serum HDL cholesterol concentrations were higher during fibrate therapy than during the statin one. During the combination therapy, the decrease in triglycerides was greater than that observed with fenofibrate alone, while the decrease in LDL cholesterol was more pronounced than that observed with atorvastatin alone. CONCLUSION: The combination of atorvastatin with micronised fenofibrate in patients with severe mixed dyslipidemia may have a favourable effect on some major coronary artery disease risk factors.en
heal.journalNameEur J Clin Pharmacolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Kiortisis-2000-Efficacy of combinat.pdf77.59 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons